"Roche said Intermune's experimental medicine danoprevir "has shown promising efficacy in preclinical and early clinical development" and should "increase flexibility" to develop and market Roche's portfolio of drugs against hepatitis C, an infection of the liver that affects around 180 million people worldwide."